CSPG4 and melanoma: CSPG4 is becoming increasingly implicated in several of the most aggressive and treatment-resistant forms of cancer, including malignant melanoma [3,17], basal-like breast cancers, leukemia, mesothelioma, glioblastoma multiforme, soft-tissue sarcomas, pancreatic carcinoma and squamous cell carcinoma of the head and neck (HNSCC) [4,18,19,20,21,22,23,24,25].